AC Immune’s Alzheimer’s drug heads to PhIIb; CytoDyn HIV drug on full hold; Syndax to raise $200Mnews2023-12-15T15:47:01+00:00December 15th, 2023|Endpoints News|
Totus Medicines closes $66M Series B to fund early-stage PI3Ka inhibitor, names new CEOnews2023-12-15T14:00:05+00:00December 15th, 2023|Endpoints News|
Reneo’s PhIIb rare disease trial failure forces layoffs, cost cuts — stock plummetsnews2023-12-15T11:47:11+00:00December 15th, 2023|Endpoints News|
Interim no more: Ashley Magargee to fill Genentech CEO post; Pfizer, Moderna make commercial leadership adjustmentsnews2023-12-15T11:44:35+00:00December 15th, 2023|Endpoints News|
Pfizer licenses mesothelin-targeted ADC from Nona Biosciences for $53M in near-term payments news2023-12-15T11:33:24+00:00December 15th, 2023|Endpoints News|
Q&A: JP Morgan’s new life sciences private capital leader on the bank’s expanding ambitions, vetting startups and Abu Dhabi’s biotech pushnews2023-12-15T11:00:16+00:00December 15th, 2023|Endpoints News|
Fractyl Health files for IPO to back obesity gene therapy, seeking to replicate GLP-1 success with one-time treatmentnews2023-12-14T22:40:21+00:00December 14th, 2023|Endpoints News|
PhRMA and BIO say Biden’s march-in proposal creates uncertainty in industrynews2023-12-14T20:23:25+00:00December 14th, 2023|Endpoints News|
Republicans pressure FDA on foreign inspections, threaten subpoena news2023-12-14T19:47:35+00:00December 14th, 2023|Endpoints News|
FDA approves high-risk neuroblastoma treatment for kids and adultsnews2023-12-14T19:47:19+00:00December 14th, 2023|Endpoints News|
